也是**一个靶向PIK3CA突变乳腺癌的药物Piqray,在欧洲获批

2020-08-01 MedSci原创 MedSci原创

与单用氟维司群相比,Piqray与氟维司群组合将中位无进展生存期(PFS)几乎增加了一倍(分别为5.7个月和11.0个月)

诺华公司宣布,欧盟委员会(EC)批准Piqray(alpelisib)与氟维司群相结合,用于治疗激素受体阳性且人表皮生长因子受体2阴性(HR+/HER2-)、PIK3CA突变、内分泌单药治疗后疾病进展的局部晚期或转移性乳腺癌男性患者和绝经后的女性患者。

Piqray是第一种也是唯一一种被专门批准用于治疗PIK3CA突变的晚期乳腺癌患者药物。全世界每年有334000人被诊断出患有晚期乳腺癌,而HR+/HER2-亚型的患者中约40%有PIK3CA突变。

此次批准基于III期SOLAR-1试验的阳性结果,与氟维司群单用相比,Piqray与氟维司群组合将中位无进展生存期(PFS)几乎增加了一倍(分别为5.7个月和11.0个月),总反应率提高了一倍以上。

图片来源:诺华官网

Piqray是磷脂酰肌醇-3-激酶(PI3K)的抑制剂,主要作用于PI3Kα(PIK3CA)。PIK3CA突变导致PI3Kα和Akt信号活化,刺激肿瘤生长并且与患者预后差密切相关。

图片来源:诺华官网

原始出处:

https://www.firstwordpharma.com/node/1744507?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1710578, encodeId=2ff31e105789b, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Wed Jan 27 12:52:44 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954104, encodeId=80c5195410444, content=<a href='/topic/show?id=778d1430033' target=_blank style='color:#2F92EE;'>#Piqray#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14300, encryptionId=778d1430033, topicName=Piqray)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Apr 25 06:52:44 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007522, encodeId=2995200e52231, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Aug 17 09:52:44 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893994, encodeId=c2d78939947a, content=PIK3CA的肺癌可以用吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5424518, createdName=ms8000000386670212, createdTime=Fri Oct 23 19:46:02 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339344, encodeId=1dcf1339344db, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Mon Aug 03 10:52:44 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805656, encodeId=2026805656fc, content=方向可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47612049883, createdName=1891eb9251m, createdTime=Sat Aug 01 20:51:08 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1710578, encodeId=2ff31e105789b, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Wed Jan 27 12:52:44 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954104, encodeId=80c5195410444, content=<a href='/topic/show?id=778d1430033' target=_blank style='color:#2F92EE;'>#Piqray#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14300, encryptionId=778d1430033, topicName=Piqray)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Apr 25 06:52:44 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007522, encodeId=2995200e52231, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Aug 17 09:52:44 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893994, encodeId=c2d78939947a, content=PIK3CA的肺癌可以用吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5424518, createdName=ms8000000386670212, createdTime=Fri Oct 23 19:46:02 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339344, encodeId=1dcf1339344db, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Mon Aug 03 10:52:44 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805656, encodeId=2026805656fc, content=方向可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47612049883, createdName=1891eb9251m, createdTime=Sat Aug 01 20:51:08 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1710578, encodeId=2ff31e105789b, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Wed Jan 27 12:52:44 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954104, encodeId=80c5195410444, content=<a href='/topic/show?id=778d1430033' target=_blank style='color:#2F92EE;'>#Piqray#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14300, encryptionId=778d1430033, topicName=Piqray)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Apr 25 06:52:44 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007522, encodeId=2995200e52231, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Aug 17 09:52:44 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893994, encodeId=c2d78939947a, content=PIK3CA的肺癌可以用吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5424518, createdName=ms8000000386670212, createdTime=Fri Oct 23 19:46:02 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339344, encodeId=1dcf1339344db, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Mon Aug 03 10:52:44 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805656, encodeId=2026805656fc, content=方向可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47612049883, createdName=1891eb9251m, createdTime=Sat Aug 01 20:51:08 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-08-17 xinmeili
  4. [GetPortalCommentsPageByObjectIdResponse(id=1710578, encodeId=2ff31e105789b, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Wed Jan 27 12:52:44 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954104, encodeId=80c5195410444, content=<a href='/topic/show?id=778d1430033' target=_blank style='color:#2F92EE;'>#Piqray#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14300, encryptionId=778d1430033, topicName=Piqray)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Apr 25 06:52:44 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007522, encodeId=2995200e52231, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Aug 17 09:52:44 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893994, encodeId=c2d78939947a, content=PIK3CA的肺癌可以用吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5424518, createdName=ms8000000386670212, createdTime=Fri Oct 23 19:46:02 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339344, encodeId=1dcf1339344db, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Mon Aug 03 10:52:44 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805656, encodeId=2026805656fc, content=方向可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47612049883, createdName=1891eb9251m, createdTime=Sat Aug 01 20:51:08 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-10-23 ms8000000386670212

    PIK3CA的肺癌可以用吗?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1710578, encodeId=2ff31e105789b, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Wed Jan 27 12:52:44 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954104, encodeId=80c5195410444, content=<a href='/topic/show?id=778d1430033' target=_blank style='color:#2F92EE;'>#Piqray#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14300, encryptionId=778d1430033, topicName=Piqray)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Apr 25 06:52:44 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007522, encodeId=2995200e52231, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Aug 17 09:52:44 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893994, encodeId=c2d78939947a, content=PIK3CA的肺癌可以用吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5424518, createdName=ms8000000386670212, createdTime=Fri Oct 23 19:46:02 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339344, encodeId=1dcf1339344db, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Mon Aug 03 10:52:44 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805656, encodeId=2026805656fc, content=方向可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47612049883, createdName=1891eb9251m, createdTime=Sat Aug 01 20:51:08 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1710578, encodeId=2ff31e105789b, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Wed Jan 27 12:52:44 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954104, encodeId=80c5195410444, content=<a href='/topic/show?id=778d1430033' target=_blank style='color:#2F92EE;'>#Piqray#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14300, encryptionId=778d1430033, topicName=Piqray)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Apr 25 06:52:44 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007522, encodeId=2995200e52231, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Aug 17 09:52:44 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893994, encodeId=c2d78939947a, content=PIK3CA的肺癌可以用吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5424518, createdName=ms8000000386670212, createdTime=Fri Oct 23 19:46:02 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339344, encodeId=1dcf1339344db, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Mon Aug 03 10:52:44 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805656, encodeId=2026805656fc, content=方向可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47612049883, createdName=1891eb9251m, createdTime=Sat Aug 01 20:51:08 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-08-01 1891eb9251m

    方向可以

    0

相关资讯

Nat Commun:HER2阳性乳腺癌在双HER2阻断期间和之后的表型变化

HER2阳性(HER2+)乳腺癌内的HER2富集型(HER2-E)亚型高度依赖HER2通路。然而,20-60%的HER2+/HER2-E肿瘤在抗HER2疗法后不能达到完全反应。在此,我们评估了PAME

中国专家为晚期难治性“最毒”乳腺癌患者燃起“生命之光”

三阴性乳腺癌被称为“最毒、最凶险”的乳腺癌,有不少患者经过多轮治疗、仍发生进展,面对“无药可救”的绝境。

Dev Cell :利用谱系示踪技术无缝隙捕捉体内肿瘤转移中的EMT过程

由于乳腺癌细胞丧失了正常的细胞特性,细胞之间的连接变得松散,容易脱落,进入血液系统或者淋巴系统进行转移,在远端器官,如肺,骨,肝等器官处形成转移灶,威胁患者生命。对乳腺癌转移方式及其机理的研究意义重大

JAMA:绝经后激素干预对女性乳腺癌发病率及死亡率的影响

长期随访发现,对于子宫切除的绝经后女性,接受结合雌激素可降低乳腺癌发病率和死亡率,但对于保留子宫的参与者,激素干预会增加乳腺癌发病率

什么是节拍化疗?节拍化疗在乳腺癌和肺癌中的研究汇总

1971年美国哈佛医学院Folkman教授首次大胆地提出抑制肿瘤血管新生可以抑制肿瘤组织持续生长转移的假说,随着研究的深入,发现如果能够连续性给予低剂量的化疗药物,可能通过有效抑制肿瘤血管生长而控制肿

Medicine:流产会增加乳腺癌的发病风险?!NO!

各种流行病学研究表明,流产与无配偶女性患乳腺癌的风险之间存在关联,但结果仍未定论。本荟萃分析在以往研究的基础上对其关联性进行了评估。